Tirzepatide, marketed as Mounjaro® by Eli Lilly, is a dual GIP/GLP-1 receptor agonist approved by the FDA in 2022 for Type 2 Diabetes (T2D) management. It uniquely targets both glycemic control and weight loss, outperforming traditional GLP-1 receptor agonists. Clinical trials, especially SURPASS-4, demonstrated significant HbA1c and body weight reduction, along with reduced mortality compared to insulin glargine. With a comparable safety profile to GLP-1RAs and similar gastrointestinal side effects, Tirzepatide offers a groundbreaking approach to T2D, with potential applications in obesity and related metabolic conditions.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Ultima-Tirzepatide by Ultima Pharmaceuticals, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
